The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
Justin Klee
Advertisement
Articles by Justin Klee
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Advanced Therapy with Apomorphine Pump in Parkinson’s Disease
2
SKY-0515 Demonstrates Sustained Mutant Huntingtin Lowering in Latest Phase 1/2 Study Update
3
Inside the Development of ISSCR’s New Parkinson Disease Stem Cell Program
4
Managing OFF Time in Parkinson’s Disease
5